EP0066296A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Non-A, non-B hepatitis-associated antigen, a conjugate therof and diagnostic reagent containing same
Assignee: Eisai Co Ltd
•
Filing: 1982-06-02
•
Granted: —
•
Expires: 2002-06-02
Abstract
Abstract A type non-A, non-B hepatitis-associated antigen is obtained by isolation and purification from non-A, non-B hepatitis autopsy liver and has the following physicochemical properties: molecular weight: 1,500,000 or more (gel filtration) sedimentation constant (10<-><1><3>): 51.5S (ultracentrifugal analysis) buoyant density (g/cm<3>): 1.15 - 1.25 (in cesium chloride and in potassium bromide) particle diameter (nm): 26 - 37 electrophoretic mobility: alpha 2 - alpha 1 globulin region (in agarose gel). A type non-A, non-B hepatitis diagnostic reagent contains, as its principal ingredient, a conjugate of the above-described antigen.
Inventors
- 👤 Junichi Tomatsu
- 👤 Tomiaki Morimoto
- 👤 Toshio Shikata
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 18:10
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5767; A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; A61K2039/54; A61K2039/555; A61K2039/55511; A61K2039/55566; C; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24234
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
85 words
An antigen associated with non-A, non-B hepatitis obtained by isolation and purification from the liver of a mammal inflected with non-A, non-B hepatitis, said antigen having the following physicochemical properties: (a) molecular weight: 1,500,000 or more, by gel filtration; (b) sedimentation constant (10 -13 ): 51.5S, by ultracentrifugal analysis; (c) buoyant density (g/cm 3 ): 1.15 - 1.25, in cesium chloride and in potassium bromide; (d) particle diameter: approximately 26-37 nm; and (e) electrophoretic mobility: α 2 - α 1 globulin region, in agarose gel.
Claim 2
Dependent Claim
85 words
An antigen associated with non-A, non-B hepatitis obtained by isolation and purification from the liver of a mammal inflected with non-A, non-B hepatitis, said antigen having the following physicochemical properties: (a) molecular weight: 1,500,000 or more, by gel filtration; (b) sedimentation constant (10 -13 ): 51.5S, by ultracentrifugal analysis; (c) buoyant density (g/cm 3 ): 1.15 - 1.25, in cesium chloride and in potassium bromide; (d) particle diameter: approximately 26-37 nm; and (e) electrophoretic mobility: α 2 - α 1 globulin region, in agarose gel.
Claim 3
Dependent Claim
52 words
A conjugate suitable for use as a diagnostic reagent for detecting non-A, non-B hepatitis comprising the antigen of claim 1 combined with a substance selected from the group consisting of fine carrier particles suitable for passive hemagglutination procedure, labelling isotopes suitable for radioimmunoassay procedure, and enzymes suitable for enzyme-lined immunoadsorbent assay procedure.
Claim 4
Dependent Claim
28 words
A conjugate as claimed in Claim2 wherein said fine carrier particles are sheep erythrocytes, said isotope is 125 I or 131 I and said enzyme is alkali phosphatase.
Claim 5
Dependent Claim
15 words
A non-A, non-B hepatitis diagnostic reagent containing as its principal ingredientthe antigen of claim 1.
Claim 6
Dependent Claim
16 words
A non-A, non-B hepatitis diagnostic reagent containing, as its principal ingredient, the conjugate of claim 2.
Claim 7
Dependent Claim
32 words
A non-A, non-B hepatitis diagnostic reagent as claimed in Claim 5 wherein said fine particles are sheep erythrocytes, said isotope is 125 I or 131 I and said enzyme is alkali phosphatase.
Claim 8
Dependent Claim
67 words
An antigen according to Claim 1, wherein said antigen is isolated and purified by: (a) slicing and homogenizing said autopsy liver; (b) centrifuging the homogenized autopsy liver to form a liver homogenate supernatant; (c) subjecting said supernatant.homogenate to column chromatography one or more times to isolate an antigen positive fraction; and (d) subjecting said antigen positive fraction to ultracentrifugation one or more times to obtain said antigen.
Claim 9
Dependent Claim
64 words
An antigen according to Claim 7, wherein in said step (c) said homogenate supernatant is eluted through an equilibrated column packed with Sephacryl S-200, concentrated, then eluted through an equilibrated column packed with Sephacryl S-300 and then concentrated a second time; and in step (d) said antigen positive fraction is subjected successively to sucrose density gradient centrifugation and then cesium chloride density gradient centrifugation.
Claim 10
Dependent Claim
26 words
An antigen according to Claim 1, Claim 7 or Claim 8, wherein said antigen has morphology substantially as shown in Figure 6 of the accompanying drawings.
Claim 11
Dependent Claim
67 words
An antigen according to Claim 1, Claim 7 or Claim 8 which forms a precipitin line with the serum of a convalescent phase from non-A, non-B hepatitis patient in the micro-Ouchterlony's method, said antigen being non-reactive with HA antibody, HBs antibody, HBe antibody, HBc antibody, 6 antibody, HC antibody, EB antibody, Arai antibody, F antibody, normal human liver homogenate supernatant antibody and various normal human plasma antibodies.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.